Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
9.92M
-
Shares change
-
+321K
-
Total reported value, excl. options
-
$469M
-
Value change
-
+$14.7M
-
Number of buys
-
40
-
Number of sells
-
-26
-
Price
-
$47.23
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2018
78 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q3 2018.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.92M shares
of 46.2M outstanding shares and own 21.46% of the company stock.
Largest 10 shareholders include MENORA MIVTACHIM HOLDINGS LTD. (2.5M shares), Consonance Capital Management LP (1.52M shares), WELLINGTON MANAGEMENT GROUP LLP (994K shares), ProQuest Associates IV LLC (789K shares), MEITAV DASH INVESTMENTS LTD (584K shares), FMR LLC (556K shares), CREDIT SUISSE AG/ (420K shares), Wildcat Capital Management, LLC (375K shares), CITADEL ADVISORS LLC (374K shares), and HIGHLINE CAPITAL MANAGEMENT, L.P. (332K shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.